Casdin Partners Master Fund, L.P. bought LAB

November 17, 2025 · Form 4 insider transaction

Casdin Partners Master Fund, L.P. bought 225,000 shares of Standard BioTools Inc. at $1.22 per share, a transaction worth $275.6K. The trade was recorded as open-market purchase and disclosed on an SEC Form 4, filed 0 days after the transaction.

Direction
Acquired (buy-side)
Shares
225,000
Price
$1.22
Total value
$275.6K
Role
SecurityCommon Stock, $0.001 par value per share
Transaction codeP: Open-market purchase
Transaction dateNovember 17, 2025
Filing dateNovember 17, 2025
Shares owned after62,975,000
OwnershipIndirect
10b5-1 planNo
AmendedNo

Footnotes

The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.2175 to $1.2299. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.; The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP.

View the original Form 4 on SEC EDGAR